Status:
COMPLETED
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Lead Sponsor:
Agendia
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-90 years
Brief Summary
The scope of this registry study is to measure chemosensitivity as defined by pCR (primary endpoint), or endocrine sensitivity as defined by partial response (decrease in longest tumor diameter or res...
Detailed Description
This will be a prospective observational, case-only study linking MammaPrint, BluePrint, TargetPrint, TheraPrint and possible additional profiles of interest to treatment response and Distant Metastas...
Eligibility Criteria
Inclusion
- Women with histologically proven breast cancer, who have started or are scheduled to start neo-adjuvant chemotherapy therapy or neo-adjuvant hormone therapy, after successful MammaPrint assay
- Age 18-90
- Written informed consent
Exclusion
- Patients who have had excisional biopsy or axillary dissection Patients with confirmed distant metastatic disease
- Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria
- Patients who have had any prior chemotherapy, radiotherapy, or endocrine therapy for the treatment of breast cancer
- Any serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease
Key Trial Info
Start Date :
July 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2021
Estimated Enrollment :
1142 Patients enrolled
Trial Details
Trial ID
NCT01479101
Start Date
July 1 2011
End Date
January 1 2021
Last Update
January 19 2021
Active Locations (76)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Center for Cancer Care
Glendale, Arizona, United States, 85306
2
21 Century Oncology
Scottsdale, Arizona, United States, 85251
3
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, United States, 94705
4
Fresno Breast Surgery
Fresno, California, United States, 93710